Gupta R C, Dixit R, Purohit S D, Saxena A
Department of Chest Diseases and Tuberculosis, J.L.N. Medical College, Ajmer.
Indian J Chest Dis Allied Sci. 2000 Jul-Sep;42(3):161-6.
Twenty-nine cases of tuberculosis developing pleural effusion (PE) during antituberculous chemotherapy (ATT) were analysed for clinical presentation and management outcome. Sixteen (55%) patients had pulmonary tuberculosis alone while rest had associated or isolated extrapulmonary tuberculosis. Thirteen (44.8%) patients developed PE during the 5th-8th week of chemotherapy and nine (31%) during 9th-12th week. Eighteen (62%) patients were on either HRZE or HRE while five (17.2%) were on SHRZ regimen before developing PE. All cases had exudative PE. Pleural fluid centrifuge was smear positive for AFB in two (6.8%) cases and culture positive for Mycobacterium tuberculosis in four (13.7%) cases. Pleural biopsy sections were negative for either AFB or tuberculous histology in 15 out of the 24 biopsies done. Twenty-four (82.7%) patients showed good response on the same ATT without modification. Development of PE during successful ATT seems to be an extension of paradoxical events having an immunological basis, which does not necessarily require any modification in chemotherapy.
对29例在抗结核化疗(ATT)期间发生胸腔积液(PE)的结核病患者的临床表现和治疗结果进行了分析。16例(55%)患者仅患有肺结核,其余患者伴有或患有肺外结核。13例(44.8%)患者在化疗第5 - 8周出现PE,9例(31%)在第9 - 12周出现。18例(62%)患者在出现PE前使用HRZE或HRE方案,5例(17.2%)使用SHRZ方案。所有病例均为渗出性PE。胸腔积液离心涂片在2例(6.8%)病例中抗酸杆菌阳性,4例(13.7%)病例结核分枝杆菌培养阳性。在24例活检中,15例胸膜活检切片抗酸杆菌或结核组织学均为阴性。24例(82.7%)患者在未调整的相同ATT方案下显示出良好反应。在成功的ATT期间发生PE似乎是具有免疫基础的矛盾事件的延伸,不一定需要对化疗进行任何调整。